Preoperative Intralesional Bevacizumab Injection in Primary Pterygium in Tunisian Patients: A Randomized Controlled Prospective Study

Overview

Journal J Curr Ophthalmol

Date 2023 Jan 16

PMID 36644467

Authors

Jihene Sayadi

Dhouha Gouider

Meher Henchiri

Racem Choura

Nadia Boujelbene

Imen Abbes

Sana Khochtali

Imene Zghal

Ines Malek

Moncef Khairallah

Leila Nacef

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess the efficacy and safety of a single preoperative intralesional bevacizumab injection as an adjuvant treatment before primary pterygium surgery.

Methods: We conducted a randomized controlled interventional study from January 2019 to December 2020. The study included a total of 60 patients (60 eyes) with primary pterygium. We defined two groups of 30 patients each. Group A received an intralesional injection of bevacizumab (Avastin), 1 month before surgery (lesion excision and conjunctival autograft). Group B (control) had only the surgical treatment. Patients were followed up 7 days (D7), 1 month (M1), 3 months (M3), and 6 months (M6) postoperatively. Pre-, per-, and postoperatively, photographs of the lesions were taken, as well as a histopathological examination. The main outcome measures were the change in functional discomfort following intralesional bevacizumab injection and pterygium recurrence. Recurrence was defined as fibrovascular tissue growth invading the cornea. Therapeutic success was defined as the absence of pterygium recurrence in M6.

Results: The mean age of the 60 patients was 54.17 ± 10.53. After bevacizumab injection, the preoperative functional discomfort score decreased significantly ( = 0.048). There was a significant improvement in grade and color intensity ( = 0.001). We noted no local nor systemic complications after intralesional injection of bevacizumab. After pterygium excision, the success rate was statistically higher in Group A ( = 0.047). There was no significant difference in either final best-corrected spectral visual acuity or astigmatism between the two groups. We noted a statistically significant association between recurrence and color intensity ( = 0.046), vascular density ( = 0.049), and the degree of elastic tissue degeneration ( = 0.040).

Conclusion: A single preoperative subconjunctival injection of bevacizumab 1 month before surgery decreases the vascularity of newly formed blood vessels and hence may reduce the recurrence rate.

Citing Articles

Oxidative stress in the eye and its role in the pathophysiology of ocular diseases.

Bohm E, Buonfiglio F, Voigt A, Bachmann P, Safi T, Pfeiffer N Redox Biol. 2023; 68:102967.

PMID: 38006824 PMC: 10701459. DOI: 10.1016/j.redox.2023.102967.

References

Chen T, Ding L, Shan G, Ke L, Ma J, Zhong Y . Prevalence and racial differences in pterygium: a cross-sectional study in Han and Uygur adults in Xinjiang, China. Invest Ophthalmol Vis Sci. 2015; 56(2):1109-17. PMC: 4329945. DOI: 10.1167/iovs.14-15994. View

Golu T, Mogoanta L, Streba C, Pirici D, Malaescu D, Mateescu G . Pterygium: histological and immunohistochemical aspects. Rom J Morphol Embryol. 2011; 52(1):153-8. View

Nuzzi R, Tridico F . Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence. J Ophthalmol. 2017; 2017:6824670. PMC: 5467320. DOI: 10.1155/2017/6824670. View

Rezvan F, Khabazkhoob M, Hooshmand E, Yekta A, Saatchi M, Hashemi H . Prevalence and risk factors of pterygium: a systematic review and meta-analysis. Surv Ophthalmol. 2018; 63(5):719-735. DOI: 10.1016/j.survophthal.2018.03.001. View

Prabhasawat P, Barton K, Burkett G, Tseng S . Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997; 104(6):974-85. DOI: 10.1016/s0161-6420(97)30197-3. View

Ozsutcu M, Ayintap E, Akkan J, Koytak A, Aras C . Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence. Indian J Ophthalmol. 2013; 62(4):407-11. PMC: 4064213. DOI: 10.4103/0301-4738.120220. View

Ozer A, Yildirim N, Erol N, Yurdakul S . Long-term results of bare sclera, limbal-conjunctival autograft and amniotic membrane graft techniques in primary pterygium excisions. Ophthalmologica. 2009; 223(4):269-73. DOI: 10.1159/000210444. View

Yang H, Lee Y, Hyon J, Kim K, Han S . Efficacy of bevacizumab injection after pterygium excision and limbal conjunctival autograft with limbal fixation suture. Graefes Arch Clin Exp Ophthalmol. 2020; 258(7):1451-1457. DOI: 10.1007/s00417-020-04704-w. View

Shenasi A, Mousavi F, Shoa-Ahari S, Rahimi-Ardabili B, Fouladi R . Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea. 2011; 30(11):1219-22. DOI: 10.1097/ICO.0b013e31820ca63f. View

10.

Mohamed T, Soliman W, Fathalla A, El Refaie A . Effect of single subconjunctival injection of bevacizumab on primary pterygium: clinical, histopathological and immunohistochemical study. Int J Ophthalmol. 2018; 11(5):797-801. PMC: 5957031. DOI: 10.18240/ijo.2018.05.13. View

11.

Besharati M, Manaviat M, Souzani A . Subconjunctival bevacizumab injection in treatment of pterygium. Acta Med Iran. 2011; 49(3):179-83. View

12.

Figueiredo R, Cohen E, Gomes J, Rapuano C, Laibson P . Conjunctival autograft for pterygium surgery: how well does it prevent recurrence?. Ophthalmic Surg Lasers. 1997; 28(2):99-104. View

13.

Enkvetchakul O, Thanathanee O, Rangsin R, Lekhanont K, Suwan-Apichon O . A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. Cornea. 2011; 30(11):1213-8. DOI: 10.1097/ICO.0b013e31821c9b44. View

14.

Patel E, Rhee M . Surgical Techniques and Adjuvants for the Management of Pterygium. Eye Contact Lens. 2021; 48(1):3-13. DOI: 10.1097/ICL.0000000000000849. View

15.

Chu W, Choi H, Bhat A, Jhanji V . Pterygium: new insights. Eye (Lond). 2020; 34(6):1047-1050. PMC: 7413326. DOI: 10.1038/s41433-020-0786-3. View

16.

Zhang X, Jiang Y, Fu Q, Zhang X, Chen Y . Efficacy of bevacizumab in the treatment of pterygium: An updated meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021; 98:107921. DOI: 10.1016/j.intimp.2021.107921. View

17.

Xu F, Li M, Yan Y, Lu K, Cui L, Chen Q . A novel technique of sutureless and glueless conjunctival autografting in pterygium surgery by electrocautery pen. Cornea. 2012; 32(3):290-5. DOI: 10.1097/ICO.0b013e31824f8c15. View

18.

Hara T, Hashimoto T, Hara T . Pterygium surgery using the principle of contact inhibition: results of 13 years' experience. Graefes Arch Clin Exp Ophthalmol. 2016; 255(3):583-590. PMC: 5323473. DOI: 10.1007/s00417-016-3558-9. View

19.

Lewallen S . A randomized trial of conjunctival autografting for pterygium in the tropics. Ophthalmology. 1989; 96(11):1612-4. DOI: 10.1016/s0161-6420(89)32667-4. View

20.

Singh P, Sarkar L, Sethi H, Gupta V . A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients. Indian J Ophthalmol. 2015; 63(10):779-84. PMC: 4728977. DOI: 10.4103/0301-4738.171508. View